key: cord-1038595-6skpuudl
authors: Wyler, Emanuel; Adler, Julia M.; Eschke, Kathrin; Alves, Gustavo Teixeira; Peidli, Stefan; Pott, Fabian; Kazmierski, Julia; Michalick, Laura; Kershaw, Olivia; Bushe, Judith; Andreotti, Sandro; Pennitz, Peter; Abdelgawad, Azza; Postmus, Dylan; Goffinet, Christine; Kreye, Jakob; Reincke, S Momsen; Prüss, Harald; Blüthgen, Nils; Gruber, Achim D.; Kuebler, Wolfgang M.; Witzenrath, Martin; Landthaler, Markus; Nouailles, Geraldine; Trimpert, Jakob
title: Insights into standards of care – dexamethasone and antibodies against COVID-19 in hamster models
date: 2021-12-20
journal: bioRxiv
DOI: 10.1101/2021.12.17.473180
sha: b9a0807aa3ed4406915e5acb5b10bd04832485ff
doc_id: 1038595
cord_uid: 6skpuudl

Rationale In face of the ongoing SARS-CoV-2 pandemic, effective and well-understood treatment options are still scarce. While vaccines have proven instrumental in fighting SARS-CoV-2, their efficacy is challenged by vaccine hesitancy, novel variants and short-lasting immunity. Therefore, understanding and optimization of therapeutic options remains essential. Objectives We aimed at generating a deeper understanding on how currently used drugs, specifically dexamethasone and anti-SARS-CoV-2 antibodies, affect SARS-CoV-2 infection and host responses. Possible synergistic effects of both substances are investigated to evaluate combinatorial treatments. Methods By using two COVID-19 hamster models, pulmonary immune responses were analyzed to characterize effects of treatment with either dexamethasone, anti-SARS-CoV-2 spike monoclonal antibody or a combination of both. scRNA sequencing was employed to reveal transcriptional response to treatment on a single cell level. Measurements and main results Dexamethasone treatment resulted in similar or increased viral loads compared to controls. Anti-SARS-CoV-2 antibody treatment alone or combined with dexamethasone successfully reduced pulmonary viral burden. Dexamethasone exhibited strong anti-inflammatory effects and prevented fulminant disease in a severe COVID-19-like disease model. Combination therapy showed additive benefits with both anti-viral and anti-inflammatory potency. Bulk and single-cell transcriptomic analyses confirmed dampened inflammatory cell recruitment into lungs upon dexamethasone treatment and identified a candidate subpopulation of neutrophils specifically responsive to dexamethasone. Conclusions Our analyses i) confirm the anti-inflammatory properties and indicate possible modes of action for dexamethasone, ii) validate anti-viral effects of anti-SARS-CoV-2 antibody treatment, and iii) reveal synergistic effects of a combination therapy and can thus inform more effective COVID-19 therapies.

A novel coronavirus (CoV), severe acute respiratory distress syndrome CoV-2) emerged in December 2019 in Wuhan, China and evolved rapidly into an 130 ongoing pandemic (1) . While development of vaccines was successful, there is still a 131 lack of approved, effective and well-understood CoV disease 2019 132 treatments (2, 3). 133 To devise successful host-directed therapeutic strategies, understanding of pathogenesis is required. For COVID-19 patients, virus-triggered exuberant cytokine 135 release and associated tissue damage play a crucial role in disease severity, e. g. hamsters were carried out as previously described (22, 23) . Treatments were applied 179 as single i.p. treatment with 30 mg/kg mAb as previously described (16) and daily i.m. 180 treatment with 2 mg/kg dexamethasone in the respective groups. Hamsters were 181 monitored daily until they reached scheduled take-out time points or defined humane 182 endpoints. Virus titers and RNA copies were determined by plaque assay and 183 quantitative RT-PCR analysis as previously described (22) . development nor did they present with severe signs of disease ( Figure 1A , B). Titers 

In order to investigate cellular mechanisms underlying these treatment effects, we next 294 performed pulmonary scRNA-seq of Roborovski hamsters for all treatment groups at 295 3 dpi. First, we evaluated the absolute content and composition of cell types by 296 measuring total cell counts of the dissociated tissue ( Figure 3A ) and relative cell type as Tnfsf10 (coding for the pro-inflammatory cytokine Trail) in neutrophils were more 346 reduced in dexamethasone treated compared to mAb treated animals.

In order to understand the changes in gene expression patterns caused by these 348 treatments, we defined, based on our Syrian hamster scRNA-seq data (25), two groups 349 of gene sets. The first was viral PAMP dependent (identified as "NF-kB-dependent"), 350 the second induced by the infection in general ("interferon-dependent") ( Figure E4F ).

Whereas the "interferon-dependent" gene expression was reduced more by mAb 352 9 compared to dexamethasone treatment, for the "NF-kB-dependent" gene set we in 353 tendency observed the opposite ( Figure 4B ). We scrutinized this effect in detail in 354 monocytic macrophages and neutrophils, and found that in neutrophils, the NF-kB-355 driven cytokine genes Cxcl10 and Tnfsf10 are particularly decreased by 356 dexamethasone, whereas the ISG Mx2 was specifically diminished by mAb treatment 357 ( Figure 4C ). For all genes, the combination treatment showed an additive effect ( Figure   358 4).

Overall, these data suggest that the reduced viral load in mAb-treated animals leads 

Among the genes that were particularly prominent in cluster 6 were the cytokines and 377 macrophage and lymphocyte attractants Csf1 and Ccl3 (37, 38) ( Figure E5C ). We 378 therefore plotted the expression of these two genes along with the ISG/NF-kB targets 379 Mx2/Tnfsf10/Cxcl10, which showed that neutrophils in cluster 6 express Csf1 and Ccl3 380 at particularly high levels ( Figure 5D ), in the same time, these cells become less 381 abundant upon dexamethasone and particularly combination treatment ( Figure 5E ).

Concomitantly, by histopathology analysis, we observed less neutrophils in the Syrian hamsters (A -E) were challenged with SARS-CoV-2 (1 x 105 pfu Wildtype (WT)) and treated once at 2 dpi with 30 mg/kg mAb CV07-209 (mAb, n = 6), daily starting at 2 dpi with 2mg/kg Dexamethasone (Dex, n = 6) or received combination treatment (Dex + mAb, n = 6). Survival rates (A) in percent of SARS-CoV-2 infected Syrian hamsters and body weight (B) development in percent after virus challenge were measured until analysis time point (5 dpi, n = 3 and 7 dpi n = 3) and displayed according to treatment group. (B) Results are displayed as mean ± SD. (C) Quantification of replication competent virus as plaque-forming units (pfu) per gram homogenized lung tissue. Dotted line marks the limit of detection (DL = 100 pfu). Titers below the detection limits were set to DL/2 = 50 pfu. Number of genomic RNA (gRNA) copies detected in homogenized lung tissue (D) and oropharyngeal swabs (E). (C -E) Results are shown as mean with range. Roborovski hamsters (F -K) were challenged with SARS-CoV-2 (1 x 105 pfu Wildtype (WT)) and treated once at 1 dpi with 30 mg/kg mAb CV07-209 (mAb, n = 6), daily starting at 1 dpi with 2 mg/kg Dexamethasone (Dex, n = 6) or received combination treatment (Dex + mAb, n = 6). Survival rates (F) in percent of SARS-CoV-2 infected Roborovski hamsters, body temperature (G) in degree Celsius and body weight (H) development in percent after virus challenge were measured until planned analysis time point (3 dpi, and 5 dpi) or until termination due to score sheet criteria (non-survivors) according to treatment group. Two hamsters from the mAb group and one hamsters from the mock-treated group were euthanized at 2 dpi (represented by orange squares (I -K)). One hamster from the mock-treated group reached end point criteria at 3 dpi and was included in 3 dpi time point analysis as planned. (1 x 105 pfu Wildtype (WT)), treated once at 1 dpi with 30 mg/kg mAb CV07-209 (mAb), daily starting at 1 dpi with 2 mg/kg Dexamethasone (Dex) or received combination treatment (Dex + mAb). At 3 dpi n = 3 Roborovski hamsters of each group were subjected to pulmonary single-cell RNA sequencing analysis. Pulmonary single cell suspensions were generated, cells were microscopically counted and total numbers per lung lobe calculated. (A) Cell count of isolated cells per lung lobe according to treatment group. Calculated numbers of indicated innate immune cells (B), T and B lymphocytes (C) and AT2 and endothelial cells (D) based on scRNA-seq determined cell frequencies ( Figure E3 ) and according to treatment group. Data display means ± SD. n = 3 per group. (A -D) Two-way ANOVA, Tukey's multiple comparisons test. * P < 0.05, ** P < 0.01, ***P < 0.001, **** P < 0.0001. (E) Edema Score resulting from semi-quantitative assessment of alveolar and perivascular edema (F) H&E stained histopathology of pulmonary vascular endothelia (upper panel) and lung parenchyma (lower panel) from Roborovski hamsters at 3 dpi. Mock and mAb treated groups had moderate to marked endothelialitis with activation and loss of endothelial cells whereas the vascular endothelium remained mostly intact in Dex and Dex + mAb treated groups. The inflammatory response was more pronounced in mock and mAb treated hamsters compared to Dex and Dex + mAb treated animals. Differences were particularly observed for infiltrating neutrophils, macrophages and, lymphocytes as well as for the degree of alveolar epithelial cell necrosis. (A) Neutrophils from the scRNA-seq data were sub-clustered using the Louvain algorithm based on their individual transcriptomes, and two-dimensional projections performed using the UMAP algorithm. Cells were coloured by their cluster identity. (B) Projection as in (A), but cells are coloured by the log10-transformed percentage of viral RNA. Overlaid are the stream arrows derived from the RNA velocity analysis. Neutrophil cluster 6 is marked with a light blue oval. (C) Changes in cellular density on the UMAP projection were calculated, and cells coloured by fold changes of the indicated Dex vs. mock. Red indicates increased density, and blue indicates decreased density. Neutrophil cluster 6 is marked with a light blue oval. (D) Graph indicates the log2-transformed fold changes of the cell counts in the respective neutrophil clusters 1-10, with all three treatments compared to mock. For example, in cluster 6 there are about one third less cells (dark blue bar at -0.6, which corresponds to log2 of 0.66) upon dexamethasone treatment. (E) Dot plots show the expression of selected genes over all hamsters in the clusters as defined in (A). The dot size indicates the fraction of cells in the clusters as indicated on the left from mock-treated animals, with ≥ one mRNA count for the respective gene. The colour represents the average expression in those cells. (F) Histopathology of Roborovski hamsters 3 days after infection revealed moderate to marked alveolar and interstitial infiltration with viable and degenerate neutrophils (black arrowheads) in mock and mAb treated animals as well as elevated numbers of alveolar macrophages (gray arrowhead). Dex and Dex + mAb treated hamsters had lower numbers of neutrophils especially in their alveolar spaces and mild to moderate numbers of neutrophils in alveolar capillaries (black arrowheads). Activated alveolar macrophages phagocytized cellular debris and cleared the inflammatory response (gray arrowhead). Scale bar = 20 µm.

A Novel Coronavirus from Patients with Pneumonia 607 in China

SARS-CoV-2 Vaccines

Antiviral Treatment for COVID-19

Cytokine Storm in COVID-19: The Current 618 Evidence and Treatment Strategies

Characteristics of lymphocyte subsets and cytokines 621 in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus 622 pneumonia (NCP)

Plasma IP-10 and MCP-3 levels are highly 626 associated with disease severity and predict the progression of COVID-19

Dexamethasone-mediated inhibition of human T 629 cell growth factor and gamma-interferon messenger RNA

Scope, quality, and inclusivity of clinical guidelines produced early in 633 the covid-19 pandemic: rapid review

Anti-glucocorticoid effects 635 of dehydroepiandrosterone (DHEA)

Determinants of 638 prolonged viral RNA shedding in hospitalized patients with SARS-CoV-2 639 infection

Dexamethasone in Hospitalized Patients with Covid-19

Yipp 648 BG, Biernaskie J. Dexamethasone modulates immature neutrophils and 649 interferon programming in severe COVID-19

Antigenicity of the SARS-CoV-2 Spike Glycoprotein

A Potent SARS-CoV-2 Neutralizing Human 656

Monoclonal Antibody That Reduces Viral Burden and Disease Severity in Syrian 657

A Therapeutic Non-665 self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-666

Fruitful Neutralizing Antibody Pipeline 668

Brings Hope To Defeat SARS-Cov-2

The monoclonal antibody combination

REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical 676 and human studies

Studies in 684 humanized mice and convalescent humans yield a SARS-CoV-2 antibody 685 cocktail

Reduced 688 Neutralization of SARS-CoV-2 Omicron Variant by Vaccine Sera

Virological 693 assessment of hospitalized patients with COVID-2019

Age-Dependent Progression of 697 SARS-CoV-2 Infection in Syrian Hamsters

The Roborovski Dwarf Hamster Is A 700 Highly Susceptible Model for a Rapid and Fatal Course of SARS

SARS-CoV-2 infection of Chinese hamsters (Cricetulus griseus) 704 reproduces COVID-19 pneumonia in a well-established small animal model

Temporal omics 710 analysis in Syrian hamsters unravel cellular effector responses to moderate 711 COVID-19

Whole Genome Assembly of the Roborovski Dwarf Hamster 715 (<em>Phodopus roborovskii</em>) Genome, an Animal Model for 716

Severe/Critical COVID-19

QuasR: quantification and annotation 718 of short reads in R

Integrated analysis of multimodal 723 single-cell data

SARS-CoV-2 infection of human ACE2-transgenic 727 mice causes severe lung inflammation and impaired function

Dexamethasone may improve 730 severe COVID-19 via ameliorating endothelial injury and inflammation: A 731 preliminary pilot study

CBP (CREB binding protein) integrates NF-kappaB 733 (nuclear factor-kappaB) and glucocorticoid receptor physical interactions and 734 antagonism

Enhancer Turnover Is Associated 736 with a Divergent Transcriptional Response to Glucocorticoid in Mouse

Serum amyloid A -a review

Crosstalk between glucocorticoids and mitogen-activated 740 protein kinase signalling pathways

RNA velocity of single cells

Generalizing RNA velocity to 747 transient cell states through dynamical modeling

Control of macrophage lineage populations by CSF-1 receptor and GM-CSF 751 in homeostasis and inflammation

Macrophage inflammatory protein-1

Diffusion maps for high-dimensional single-cell 755 analysis of differentiation data

SCANPY: large-scale single-cell gene expression 757 data analysis

The 759

Molecular Signatures Database (MSigDB) hallmark gene set collection

Glucocorticosteroids 762 enhance replication of respiratory viruses: effect of adjuvant interferon

Corman VM, Stenzel W. Association Between SARS-CoV-2 Infection and

Immune-Mediated Myopathy in Patients Who Have Died

Associations of clinical characteristics and treatment 771 regimens with the duration of viral RNA shedding in patients with COVID-19. Int 772

Impact of dexamethasone on SARS-CoV-2 776 concentration kinetics and antibody response in hospitalized COVID-19 777 patients: results from a prospective observational study

SARS-CoV-2 infection triggers 789 profibrotic macrophage responses and lung fibrosis

Effectiveness of 792 corticosteroids on chest high-resolution computed tomography features of 793 COVID-19 pneumonia

Neutrophils and COVID-19: The road so 796 far

Animal Models for COVID-19: Hamsters, Mouse, Ferret, Mink, Tree Shrew, and 799 Non-human Primates

Ultra-and micro-structural changes of respiratory tracts in SARS-CoV-2 802 infected Syrian hamsters

Latent 807 Class Analysis Reveals COVID-19-related Acute Respiratory Distress 808

Syndrome Subgroups with Differential Responses to Corticosteroids